Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

http://news.ft.com/cms/s/5d32d9d6-e643-11da-a36e-0000779e2340.html
Osmetech, the healthcare diagnostics group, firmed up 1.1 per cent to 22p after house broker ABN Amro initiated coverage with a buy recommendation and a 30p target price. The broker believes strong newsflow over the next 12 months will help highlight the value of Osmetechs molecular diagnostic assets.

http://www.timesonline.co.uk/article/0,,2095-2168219,00.html

USS increased their position

Osmetech PLC
26 May 2006

Osmetech plc ('Osmetech' or 'the Company')

The Company has been notified that following the acquisition of 720,000 ordinary
shares, Universities Superannuation Scheme Limited now has an interest in
5,500,000 Osmetech ordinary shares. The shares are registered under Chase
Nominees Ltd (USS).

The total holding represents approximately 4.17 per cent of the Company's issued
ordinary share capital.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 7,700,000(5.84) Universities S S LTD 5,500,000(4.17) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 62,405,985(47.28)

Looks as if the three blind mice have in fact got perfect eyesight.

Share price down to a lowly 18.5p after news of yet another fund raising exercise - diluting existing shareholdings and raising the number of shares in issue by over 50%.

Yuk.

well the rampers have shown they lack any sort of judgement. RAMP RAMP here and on competitors site. If anyone dared to question their so called wisdom they were banned from posting. This episode shows what idiots they are. I continue to hold.

Back to 30p+ very soon...IMHO.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 7,700,000(5.84) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 65,805,985(49.86)

Can you keep that table up to date please!

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 17,985,541 (13.65) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) Roche 2,444,688 (1.8) Total 76,091,526(57.67)

after todays buying i suspect it will be out of date again very very soon!

Buy signal triggered for OMH (Osmetech) on the 3 box. Upside price objective works out around 33p!! Good low risk / high reward entry point .

Rated as a BUY in IC this week by the way, (or Good Value) can't remember which.

From the IC

23 June 2006

Osmetech in cash call


Osmetech shares fell 4 per cent after the company announced that it's raising 12.8m at 18p, an increase of 53.9 per cent in its share capital. The new funds will provide working capital for the company, which admitted that without the fund-raising it would be "unable to trade much beyond August 2006". Management says that it needs the cash to help fund new product launches, and improve its negotiating position in out-licensing opportunities.



Osmetech stated at its full-year results in March that it would need to raise funds. So, at 18p, the shares remain good value. BUY

SCREAMING BUY...

Looks like the major holders table will need another update...
http://moneyam.uk-wire.com/cgi-bin/articles/200607041225366403F.html

MajorShareHolders No. Shares(%) Gartmore 22,016,240(16.70) Schroder 18,874,284 (14.32) UBS AG 17,985,541 (13.65) Universities S S LTD 8,900,000(6.75) Pershing Keen 5,870,773 (4.45) BCSSS 4,301,289(3.26) Roche 2,444,688 (1.8) Total 80,392,815(60.93)

Trading Statement

RNS Number:9033F
Osmetech PLC
10 July 2006



Osmetech plc - Trading Update

Osmetech plc, the international healthcare diagnostics group will provide the
following update during its Extraordinary General Meeting at 11:00am today:

During the first six months of 2006, the Group has continued to build on the
strong sales growth achieved in 2005. Sales for the 6 month period ended 30 June
2006 are 36% ahead of the corresponding period in 2005.

The majority of sales relate to the Critical Care division where sales exceeded
$8.6m, up by 34% on the corresponding period in 2005, with sales increasing in
both human and veterinary markets.

As planned, in the first half of the year, Osmetech's Molecular Diagnostics
Division launched its FDA approved eSensor Cystic Fibrosis Carrier Detection
test and eSensor 4800 DNA Detection instrument and OPTI TUBE product for use in
the Roche LightCycler as a cost-effective and safe alternative to the Roche
glass capillaries. Our OPTI GENE instrument and proprietary consumable system
for the rapid detection of DNA and RNA targets will be launched with
thrombophilia assays at the American Association of Clinical Chemists (AACC)
Conference in Chicago later this month.

We are confident of further sales growth for the Group in the second half of the
year. We expect our Critical Care division to report a record sales performance
during the next six month period with a growing contribution from our new OPTI
LION and OPTI R instruments and further strong sales growth of the VetStat
product by our distribution partner, IDEXX, in the veterinary market. We also
expect to report early commercial success with our new molecular diagnostics
products as we start to build a significant presence in this rapidly growing
market.

Ends

Osmetech says US biotech fund Efficacy holds almost 9 pct of co

LONDON (AFX) - Diagnostics company Osmetech PLC said the Efficacy Biotech
Fund of California-based Efficacy Capital Ltd now owns 18 mln shares or 8.876
pct of the company.
newsdesk@afxnews.com
ak

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 21,518,671(10.61) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 107,921,878(53.21)

UBS Increase of Holding

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 23,797,239 (11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 110,200,446 (54.34)

UBS Increase of Holding